Mydrat-J Eye Drops
Pack Size: 5ML
ATROPINE SULPHATE OPHTHALMIC SOLUTION USP 0.01% WN
- Least Risk of Accommodation Loss
- Better tolerability than 0.05% & 0.025%
- Started at the first sign of Progressive Myopia
- Best if Started Between 5-10 years
- Least Risk of Rebound Myopia
- Clinically proven and recommend by WSPOS, AAO, APAO
- Convenient once-a-day dosage
- No Clinically Significant Visual Side Effects
- Formulated with a US FDA Compliant AlKOPINE SOURCE
- Reduces the progression of Myopia in the 2.00D to 6.00D range
REFERENCES:
- Audrey Chia, Oing-Shu Lu, and Donald Tan. "Five-Year Clinical Trial on Atropine for the Treatment of Myopia-Myopia Control with Atropine 0.01% Eye drops Ophthalmology 2016 Feb, 123(2);391.9"
- Stacy L. Pineles, Raymond T. Kraker, Deborah K. VanderVeen, Amy K. Hutson, Jennifer A. Galvin, Lorri B. Wilson and Scott R. Lambert. "Atropine for the Prevention of Myopia Progress. Children. A Report by the American Academy of Ophthalmology." Ophthalmology 2017; 124.1857-1866
- Donald Tan, SuAnn Tay, Kai-Lyn Lohan, and Audrey Chia. "Topical Atropine in the Control of Myopia-Review Article" Asia-Pacific Journal of Ophthalmology Volume 5. Number 6. November/December 2016
- Nicola Parry, K. David Epley, MD, R. Michael Siatkowski and Donald Tan. "How to Use Low-Dose Atropine to Slow Myopic Progression in Kids-Clinical Update". Eye Net Magazine (American Academy of Ophthalmology). December 2016
- WSPOS Myopia Consensus Statement. wspos.org, April 2016
- Chia A, Chua W H, Liew, et al., Atropine for the treatment of childhood myopia, Am. J. ophthalmol 2014:157:451-7.
- Luo Y, Yin Z, Zhang J, et al. Differential Impact of 0.01% and 0.05% Atropine Eye drops on Ocular Surface in Young Adults. Transl Vis Sci Technol. 2024;13(4):22. doi:10.1167/tvst.13.4.22
- Joachimsen L, Farassat N, Bleul T, Böhringer D, Lagrèze WA, Reich M. Side effects of topical atropine 0.05% compared to 0.01% for myopia control in German school children: a pilot study. Int Ophthalmol. 2021;41(6):2001-2008. doi:10.1007/s10792-021-01755-8
BAK FREE
Therapeutic Indications / RXn
1. Delay for progression in Myopia
